Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial.
Hong JY, Cho HJ, Sa JK, Liu X, Ha SY, Lee T, Kim H, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Park HC, Kang TW, Rhim H, Lee SJ, Cristescu R, Lee J, Paik YH, Lim HY.
Hong JY, et al. Among authors: paik yh, paik sw.
Genome Med. 2022 Jan 6;14(1):1. doi: 10.1186/s13073-021-00995-8.
Genome Med. 2022.
PMID: 34986867
Free PMC article.
Clinical Trial.